Novartis 2026 Guidance a Bit Soft on Earnings -- Market Talk

Dow Jones
02/04

0803 GMT - Novartis's guidance for this year is a bit soft on core earnings before interest and taxes, Morgan Stanley analysts Thibault Boutherin and Sarita Kapila write in a research note. The Swiss drugmaker also reported some minor delays in trial results that could cause shares to underperform, they say. The company's forecast of a decline in core EBIT "reflects the impact of [loss of patent exclusivity] and expected margin dilution from the Avidity acquisition," the analysts add. (william.gray@wsj.com)

 

(END) Dow Jones Newswires

February 04, 2026 03:04 ET (08:04 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10